

412 Rec'd PCT/PTO 0 2 JUL 1999 <sup>PCT</sup>



PATENT

Attorney Docket No.: FJN-070

RECEIVED

OCT 06 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Yamaguchi et al.

SERIAL NO.: 09/202,455

GROUP NO.: Not yet assigned.

FILING DATE: December 15, 1998

EXAMINER: Not yet assigned.

TITLE: NOVEL PROTEIN AND METHOD FOR PRODUCING THE PROTEIN

TECH CENTER 1600/2900

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8


I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on this 30th day of June, 1999.

*Olivia J. Mannion*  
Olivia J. Mannion

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith are: Transmittal Form (1 page); Information Disclosure Statement (2 pages); Form PTO - 1449 (1 page); References Labeled BA and CA to CE; and a mailroom postcard.



# TRANSMITTAL FORM

Application Serial Number	09/202,455
Filing Date	December 15, 1998
First Named Inventor	Yamaguchi et al.
Group Art Unit	Not yet assigned.
Examiner Name	Not yet assigned.
Attorney Docket No.	FJN-070


## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets _____]	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> To Convert to a Provisional Application	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> Form PTO-1449	<input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application	<input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8
<input checked="" type="checkbox"/> Copies of IDS Citations	<input type="checkbox"/> Small Entity Statement	<input type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> After Allowance Communication to Group	


## CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110  
Tel. No.: (617) 248-7000  
Fax No.: (617) 248-7100

## SIGNATURE BLOCK

Respectfully submitted,  
  
Jennifer L. Dupré  
Attorney for the Applicants  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110

Date: June 30, 1999  
Reg. No.: 41,722  
Tel. No.: (617) 248-7216  
Fax No.: (617) 248-7100



PATENT  
Attorney Docket No. FJN-070

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Yamaguchi et al.  
SERIAL NO.: 09/202,455 GROUP NO.: Not yet assigned.  
FILING DATE: December 15, 1998 EXAMINER: Not yet assigned.  
TITLE: NOVEL PROTEIN AND METHOD FOR PRODUCING THE PROTEIN

#5  
MQJ  
10/12/99

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. §1.97, Applicants hereby make of record the references listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the references are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **Filing Date** or before the mailing date of the **First Office Action** on the merits; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under Rule 1.17(p), namely **\$240.00**, is included herein, or
- ☐ (3) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, **AND**
- ☐ Applicant hereby Petitions the Commissioner to accept and consider the attached Information Disclosure Statement, **AND**
- ☐ the requisite Statement is below, **AND**

☐ the requisite petition fee due under Rule 1.17(i)(I), namely **\$130.00** is included herein.

It is respectfully requested that each of the references shown on the attached Form PTO-1449 be made of record in this application.

### STATEMENT

As required under §1.97(e), Applicants, through the undersigned, hereby state either that [check the appropriate space]:

- ☐ 1. [E]ach item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application **not more than** three months prior to the filing date of the Information Disclosure Statement; or
- ☐ 2. [N]o item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any** individual designated in §1.56(c) **more than** three months prior to the filing of the Information Disclosure Statement.

### FEE AUTHORIZATION


Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 20-0531. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

Date: June 30 1999  
Reg. No. 41,722

Tel. No.: (617) 248-7216  
Fax No.: (617) 248-7100

DUPRE3999/73.816072-1

  
Jennifer L. Dupré  
Attorney for the Applicants  
Testa, Hurwitz, & Thibeault, LLP  
High Street Tower  
125 High Street  
Boston, Massachusetts 02110

<b>FORM PTO - 1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>				ATTORNEY DOCKET NO.: FJN-070  APPLICANTS: Yamaguchi et al.  SERIAL NO.: 09/202,455  FILING DATE: December 15, 1998  GROUP: Not yet assigned.			
---	--	--	--	--	--	--	--

O T P E  
 JUL 02 1999  
 JCA33  
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS									
EXAM. INIT.	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N	
	BA	WO96/26217	08/29/96	PCT			No	No	

OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	CA	Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", <u>Nature</u> , Vol. 390, November 13, 1997, pp. 175-179.
	CB	Wong et al., "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cell", <u>J.Biol. Chem.</u> , Vol. 272, No. 40, October 28, 1997, pp. 24727-25408.
	CC	Tsuda et al., "Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis", <u>Biochem. Biophys. Res. Commun.</u> , Vol. 234, No. 1, May 8, 1997, p. 137-142.
	CD	Kaji et al., "Insulin-like growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid hormone", <u>Journal of Cellular Physiology</u> , Vol. 172, No. 1, July 10, 1997, pp. 55-62.
	CE	International Search Report for PCT/JP98/01728

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------